---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-25-044596"
form_type: "8-K"
ticker: "RNAZ"
cik: "0001829635"
company_name: "Transcode Therapeutics, Inc."
filed_at: "2025-05-05T23:59:59+00:00"
generated_at: "2026-05-22T18:43:06.644544+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# TransCode Therapeutics announces 1-for-28 reverse stock split effective May 15, 2025

## Summary
- Reverse split at 1-for-28 ratio; effective 12:01 a.m. ET on May 15, 2025.
- Outstanding shares reduced from 23,341,336 to approximately 833,620; par value unchanged.
- No fractional shares issued; rounding up to nearest whole share for record holders.
- Split intended to meet Nasdaq minimum bid price requirement; CUSIP changes to 89357L501.
- Stockholder approval obtained May 2, 2025; trading symbol remains RNAZ.

## SEC filing metadata
- accession: 0001104659-25-044596
- form_type: 8-K
- ticker: RNAZ
- cik: 0001829635
- company_name: Transcode Therapeutics, Inc.
- filed_at: 2025-05-05T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 3.03, 5.03, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829635/000110465925044596/0001104659-25-044596-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829635/000110465925044596/tm2514038d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-25-044596
- JSON: https://secwatch.observer/filing/0001104659-25-044596.json
- Plain text: https://secwatch.observer/filing/0001104659-25-044596.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.